MedPath

Moderna

Moderna logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public, Subsidiary
Established
2010-01-01
Employees
5.6K
Market Cap
$30.3B
Website
http://www.modernatx.com
Introduction

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure

Phase 1
Completed
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
Biological: Placebo
Biological: mRNA-1653
First Posted Date
2019-10-30
Last Posted Date
2023-02-03
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
51
Registration Number
NCT04144348
Locations
πŸ‡ΊπŸ‡Έ

Central Research Associates Inc, Birmingham, Alabama, United States

πŸ‡ΊπŸ‡Έ

Meridian Clinical Research, Norfolk, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Clinical Research Prime, Idaho Falls, Idaho, United States

and more 13 locations

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Phase 1
Completed
Conditions
Zika Virus
Interventions
Other: Placebo
Biological: mRNA-1893
First Posted Date
2019-08-22
Last Posted Date
2024-08-21
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
120
Registration Number
NCT04064905
Locations
πŸ‡ΊπŸ‡Έ

Meridan Clinical Research, Omaha, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Benchmark Research, Fort Worth, Texas, United States

πŸ‡΅πŸ‡·

Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Phase 2
Recruiting
Conditions
Melanoma
Interventions
First Posted Date
2019-04-01
Last Posted Date
2025-06-08
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
267
Registration Number
NCT03897881
Locations
πŸ‡ΊπŸ‡Έ

University of Arizona, Tucson, Arizona, United States

πŸ‡ΊπŸ‡Έ

California Pacific Medical Center Research Institute -CPMCRI, San Francisco, California, United States

πŸ‡ΊπŸ‡Έ

Angeles Clinic and Research Institute, Santa Monica, California, United States

and more 19 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Phase 1
Completed
Conditions
Prevention of Chikungunya Virus Infection
Interventions
Other: Placebo
Biological: mRNA-1944
First Posted Date
2019-02-04
Last Posted Date
2021-07-07
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
39
Registration Number
NCT03829384
Locations
πŸ‡ΊπŸ‡Έ

PPD Phase 1 Clinical Research Unit, Austin, Texas, United States

Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia

Phase 1
Withdrawn
Conditions
Metabolism, Inborn Errors
Methylmalonic Acidemia (MMA)
Interventions
Biological: mRNA-3704
First Posted Date
2019-01-22
Last Posted Date
2020-11-13
Lead Sponsor
ModernaTX, Inc.
Registration Number
NCT03810690

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1
Active, not recruiting
Conditions
Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Interventions
First Posted Date
2018-11-14
Last Posted Date
2025-05-15
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
134
Registration Number
NCT03739931
Locations
πŸ‡ΊπŸ‡Έ

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

πŸ‡ΊπŸ‡Έ

Providence St. John's Health Center, Santa Monica, California, United States

πŸ‡ΊπŸ‡Έ

University of Colorado Denver, Aurora, Colorado, United States

and more 21 locations

"The MaP Study": Mapping the Patient Journey in MMA and PA

Completed
Conditions
Propionic Acidemia
Methylmalonic Acidemia
First Posted Date
2018-04-02
Last Posted Date
2021-08-02
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
97
Registration Number
NCT03484767
Locations
πŸ‡ΊπŸ‡Έ

Stanford Health Services, Stanford, California, United States

πŸ‡ΊπŸ‡Έ

Emory Univeristy, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 14 locations

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

Phase 1
Completed
Conditions
Human Metapneumovirus and Human Parainfluenza Infection
Interventions
Other: Placebo
Biological: mRNA-1653
First Posted Date
2018-01-08
Last Posted Date
2020-02-06
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
124
Registration Number
NCT03392389
Locations
πŸ‡ΊπŸ‡Έ

Meridian Clinical Research, LLC, Omaha, Nebraska, United States

πŸ‡ΊπŸ‡Έ

Benchmark Research, Fort Worth, Texas, United States

Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults

Phase 1
Completed
Conditions
Cytomegalovirus Infection
Interventions
Biological: mRNA-1647
Biological: mRNA-1443
Other: Placebo
First Posted Date
2017-12-22
Last Posted Date
2021-01-15
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
181
Registration Number
NCT03382405
Locations
πŸ‡ΊπŸ‡Έ

Research Centers of America, Hollywood, Florida, United States

πŸ‡ΊπŸ‡Έ

Advanced Clinical Research, Meridian, Idaho, United States

πŸ‡ΊπŸ‡Έ

Optimal Research, Peoria, Illinois, United States

and more 1 locations

Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Influenza
Interventions
Biological: VAL-339851
Other: Placebo
First Posted Date
2017-11-17
Last Posted Date
2021-01-11
Lead Sponsor
ModernaTX, Inc.
Target Recruit Count
156
Registration Number
NCT03345043
Locations
πŸ‡ΊπŸ‡Έ

Miami Research Associates, Miami, Florida, United States

Β© Copyright 2025. All Rights Reserved by MedPath